{"title":"探索儿科重症监护病房收治的儿科癌症患者的危险因素:来自一项多中心观察性研究的见解,显示与机械通气无关。","authors":"Angela Amigoni, Sara Boscato, Maria Cristina Mondardini, Francesca Cavagnero, Luca Marchetto, Veronica Biassoni, Carolina Birolo, Gabriella Bottari, Manuela Corno, Stefania Ferrario, Giorgia Maiolo, Alessia Montaguti, Emanuele Rossetti, Immacolata Rulli, Raffaella Sagredini, Stefania Spaggiari, Luisa Vatiero, Gianluca Vigna, Matteo Martinato, Dario Gregori, Marta Pillon, Rosanna Irene Comoretto","doi":"10.1186/s44158-025-00275-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To analyze risk factors for adverse outcomes in a nationally representative sample of pediatric cancer patients admitted to the PICU.</p><p><strong>Methods: </strong>An observational study composed of a 2-year retrospective phase and a 2-year prospective phase was conducted before and during PICU admission in Italian PICUs.</p><p><strong>Results: </strong>We included 518 patients, median age 7.2 years (IQR 2.5-12.6). Main diagnosis: solid tumors (51%) and acute lymphoblastic leukemia (23%). Nineteen percent underwent stem cell transplantation (HSCT). Main causes of admission were respiratory failure (33%) and neurological impairment (24%). In-PICU mortality was 15%, higher in HSCT (41%) and non-solid cancer (25%). Pre-PICU mortality risk factors included HSCT (OR 3.48, 95%CI 1.5-8.11), higher Pediatric Overall Performance Category (POPC) (OR 1.72, 95%CI 1.23-2.42), and Pediatric Index of Mortality 3 (PIM-3) score (OR 1.03, 95%CI 1.01-1.06). In-PICU mortality risk factors included multiple organ failure (MOF) (OR 4.83, 95%CI 1.66-15.71), and cardiac arrest (OR 82.16, 95%CI 14.19-1594.61). The use of MV does not appear to be associated with increased mortality. Longer PICU LOS was associated with pre-admission acute respiratory distress syndrome (p < 0.001), renal failure (p = 0.024), POPC (p = 0.007) and PIM 3 (p < 0.001), and in-PICU use of total parenteral nutrition (p = 0.036), and duration of mechanical ventilation (MV) (p < 0.001).</p><p><strong>Conclusions: </strong>HSCT, non-solid tumor, higher PIM-3, and POPC on admission, MOF, and history of cardiac arrest were associated with poorer outcome. The use of MV does not appear to be associated with increased mortality.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov ID NCT04581655, October 7, 2020.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"5 1","pages":"63"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring risk factors for pediatric cancer patients admitted to the Pediatric Intensive Care Unit: insight from a multicenter observational study revealing no association with mechanical ventilation.\",\"authors\":\"Angela Amigoni, Sara Boscato, Maria Cristina Mondardini, Francesca Cavagnero, Luca Marchetto, Veronica Biassoni, Carolina Birolo, Gabriella Bottari, Manuela Corno, Stefania Ferrario, Giorgia Maiolo, Alessia Montaguti, Emanuele Rossetti, Immacolata Rulli, Raffaella Sagredini, Stefania Spaggiari, Luisa Vatiero, Gianluca Vigna, Matteo Martinato, Dario Gregori, Marta Pillon, Rosanna Irene Comoretto\",\"doi\":\"10.1186/s44158-025-00275-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To analyze risk factors for adverse outcomes in a nationally representative sample of pediatric cancer patients admitted to the PICU.</p><p><strong>Methods: </strong>An observational study composed of a 2-year retrospective phase and a 2-year prospective phase was conducted before and during PICU admission in Italian PICUs.</p><p><strong>Results: </strong>We included 518 patients, median age 7.2 years (IQR 2.5-12.6). Main diagnosis: solid tumors (51%) and acute lymphoblastic leukemia (23%). Nineteen percent underwent stem cell transplantation (HSCT). Main causes of admission were respiratory failure (33%) and neurological impairment (24%). In-PICU mortality was 15%, higher in HSCT (41%) and non-solid cancer (25%). Pre-PICU mortality risk factors included HSCT (OR 3.48, 95%CI 1.5-8.11), higher Pediatric Overall Performance Category (POPC) (OR 1.72, 95%CI 1.23-2.42), and Pediatric Index of Mortality 3 (PIM-3) score (OR 1.03, 95%CI 1.01-1.06). In-PICU mortality risk factors included multiple organ failure (MOF) (OR 4.83, 95%CI 1.66-15.71), and cardiac arrest (OR 82.16, 95%CI 14.19-1594.61). The use of MV does not appear to be associated with increased mortality. Longer PICU LOS was associated with pre-admission acute respiratory distress syndrome (p < 0.001), renal failure (p = 0.024), POPC (p = 0.007) and PIM 3 (p < 0.001), and in-PICU use of total parenteral nutrition (p = 0.036), and duration of mechanical ventilation (MV) (p < 0.001).</p><p><strong>Conclusions: </strong>HSCT, non-solid tumor, higher PIM-3, and POPC on admission, MOF, and history of cardiac arrest were associated with poorer outcome. The use of MV does not appear to be associated with increased mortality.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov ID NCT04581655, October 7, 2020.</p>\",\"PeriodicalId\":73597,\"journal\":{\"name\":\"Journal of Anesthesia, Analgesia and Critical Care (Online)\",\"volume\":\"5 1\",\"pages\":\"63\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Anesthesia, Analgesia and Critical Care (Online)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s44158-025-00275-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Anesthesia, Analgesia and Critical Care (Online)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s44158-025-00275-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Exploring risk factors for pediatric cancer patients admitted to the Pediatric Intensive Care Unit: insight from a multicenter observational study revealing no association with mechanical ventilation.
Background: To analyze risk factors for adverse outcomes in a nationally representative sample of pediatric cancer patients admitted to the PICU.
Methods: An observational study composed of a 2-year retrospective phase and a 2-year prospective phase was conducted before and during PICU admission in Italian PICUs.
Results: We included 518 patients, median age 7.2 years (IQR 2.5-12.6). Main diagnosis: solid tumors (51%) and acute lymphoblastic leukemia (23%). Nineteen percent underwent stem cell transplantation (HSCT). Main causes of admission were respiratory failure (33%) and neurological impairment (24%). In-PICU mortality was 15%, higher in HSCT (41%) and non-solid cancer (25%). Pre-PICU mortality risk factors included HSCT (OR 3.48, 95%CI 1.5-8.11), higher Pediatric Overall Performance Category (POPC) (OR 1.72, 95%CI 1.23-2.42), and Pediatric Index of Mortality 3 (PIM-3) score (OR 1.03, 95%CI 1.01-1.06). In-PICU mortality risk factors included multiple organ failure (MOF) (OR 4.83, 95%CI 1.66-15.71), and cardiac arrest (OR 82.16, 95%CI 14.19-1594.61). The use of MV does not appear to be associated with increased mortality. Longer PICU LOS was associated with pre-admission acute respiratory distress syndrome (p < 0.001), renal failure (p = 0.024), POPC (p = 0.007) and PIM 3 (p < 0.001), and in-PICU use of total parenteral nutrition (p = 0.036), and duration of mechanical ventilation (MV) (p < 0.001).
Conclusions: HSCT, non-solid tumor, higher PIM-3, and POPC on admission, MOF, and history of cardiac arrest were associated with poorer outcome. The use of MV does not appear to be associated with increased mortality.
Trial registration: ClinicalTrials.gov ID NCT04581655, October 7, 2020.